Literature DB >> 18615011

Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects.

W Gordon Frankle1, Raymond Y Cho, Rajesh Narendran, N Scott Mason, Shivangi Vora, Maralee Litschge, Julie C Price, David A Lewis, Chester A Mathis.   

Abstract

Accumulating evidence indicates that synchronization of cortical neuronal activity at gamma-band frequencies is important for various types of perceptual and cognitive processes and that GABA-A receptor-mediated transmission is required for the induction of these network oscillations. In turn, the abnormalities in GABA transmission postulated to play a role in psychiatric conditions such as schizophrenia might contribute to the cognitive deficits seen in this illness. We measured the ability to increase GABA in eight healthy subjects by comparing the binding of [(11)C]flumazenil, a positron emission tomography (PET) radiotracer specific for the benzodiazepine (BDZ) site, at baseline and in the presence of an acute elevation in GABA levels through the blockade of the GABA membrane transporter (GAT1). Preclinical work suggests that increased GABA levels enhance the affinity of GABA-A receptors for BDZ ligands (termed 'GABA shift'). Theoretically, such an increase in the affinity of GABA-A receptors should be detected as an increase in the binding of a GABA-A BDZ-receptor site-specific PET radioligand. GAT1 blockade resulted in significant increases in mean (+/- SD) [(11)C]flumazenil-binding potential (BP(ND)) over baseline in brain regions representing the major functional domains of the cerebral cortex: association cortex +15.2+/-20.2% (p=0.05), sensory cortex +13.5+/-15.5% (p=0.03) and limbic (medial temporal lobe, MTL) +16.4+/-20.2% (p=0.03). The increase in [(11)C]flumazenil-BP(ND) was not accounted for by differences in the plasma-free fraction (f(P); paired t-test p=0.24) or changes in the nonspecific binding (pons V(T), p=0.73). Moreover, the ability to increase GABA strongly predicted (r=0.85, p=0.015) the ability to entrain cortical networks, measured through EEG gamma synchrony during a cognitive control task in these same subjects. Although additional studies are necessary to further validate this technique, these data provide preliminary evidence of the ability to measure in vivo, with PET, acute fluctuations in extracellular GABA levels and provide the first in vivo documentation of a relationship between GABA neurotransmission and EEG gamma-band power in humans.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18615011      PMCID: PMC2754778          DOI: 10.1038/npp.2008.104

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  60 in total

1.  Subanesthetic ketamine does not affect 11C-flumazenil binding in humans.

Authors:  Elina Salmi; Jaakko W Långsjö; Sargo Aalto; Kjell Någren; Liisa Metsähonkala; Kaike K Kaisti; Esa R Korpi; Jarmo Hietala; Harry Scheinin
Journal:  Anesth Analg       Date:  2005-09       Impact factor: 5.108

2.  Perisomatic feedback inhibition underlies cholinergically induced fast network oscillations in the rat hippocampus in vitro.

Authors:  Edward O Mann; Jillian M Suckling; Norbert Hajos; Susan A Greenfield; Ole Paulsen
Journal:  Neuron       Date:  2005-01-06       Impact factor: 17.173

3.  Coherence of gamma-band EEG activity as a basis for associative learning.

Authors:  W H Miltner; C Braun; M Arnold; H Witte; E Taub
Journal:  Nature       Date:  1999-02-04       Impact factor: 49.962

4.  Simplified reference tissue model for PET receptor studies.

Authors:  A A Lammertsma; S P Hume
Journal:  Neuroimage       Date:  1996-12       Impact factor: 6.556

Review 5.  Cortical inhibitory neurons and schizophrenia.

Authors:  David A Lewis; Takanori Hashimoto; David W Volk
Journal:  Nat Rev Neurosci       Date:  2005-04       Impact factor: 34.870

6.  Effects of vigabatrin intake on brain GABA activity as monitored by spectrally edited magnetic resonance spectroscopy and positron emission tomography.

Authors:  O M Weber; A Verhagen; C O Duc; D Meier; K L Leenders; P Boesiger
Journal:  Magn Reson Imaging       Date:  1999-04       Impact factor: 2.546

7.  In vivo modulation of benzodiazepine receptor function after inhibition of endogenous gamma-aminobutyyric acid synthesis.

Authors:  M Bottlaender; L Schmid; C Fuseau; D Fournier; E Brouillet; M Mazière
Journal:  Eur J Pharmacol       Date:  1997-02-19       Impact factor: 4.432

8.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.

Authors:  A Breier; T P Su; R Saunders; R E Carson; B S Kolachana; A de Bartolomeis; D R Weinberger; N Weisenfeld; A K Malhotra; W C Eckelman; D Pickar
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-18       Impact factor: 11.205

9.  Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects.

Authors:  N D Volkow; G J Wang; J S Fowler; J Logan; S J Gatley; R Hitzemann; A D Chen; S L Dewey; N Pappas
Journal:  Nature       Date:  1997-04-24       Impact factor: 49.962

10.  A decrease of reelin expression as a putative vulnerability factor in schizophrenia.

Authors:  F Impagnatiello; A R Guidotti; C Pesold; Y Dwivedi; H Caruncho; M G Pisu; D P Uzunov; N R Smalheiser; J M Davis; G N Pandey; G D Pappas; P Tueting; R P Sharma; E Costa
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

View more
  33 in total

Review 1.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

2.  In vivo ketamine-induced changes in [¹¹C]ABP688 binding to metabotropic glutamate receptor subtype 5.

Authors:  Christine DeLorenzo; Nicole DellaGioia; Michael Bloch; Gerard Sanacora; Nabeel Nabulsi; Chadi Abdallah; Jie Yang; Ruofeng Wen; J John Mann; John H Krystal; Ramin V Parsey; Richard E Carson; Irina Esterlis
Journal:  Biol Psychiatry       Date:  2014-07-10       Impact factor: 13.382

3.  External awareness and GABA--a multimodal imaging study combining fMRI and [18F]flumazenil-PET.

Authors:  Christine Wiebking; Niall W Duncan; Pengmin Qin; Dave J Hayes; Oliver Lyttelton; Paul Gravel; Jeroen Verhaeghe; Alexey P Kostikov; Ralf Schirrmacher; Andrew J Reader; Malek Bajbouj; Georg Northoff
Journal:  Hum Brain Mapp       Date:  2012-09-21       Impact factor: 5.038

4.  Awake nonhuman primate brain PET imaging with minimal head restraint: evaluation of GABAA-benzodiazepine binding with 11C-flumazenil in awake and anesthetized animals.

Authors:  Christine M Sandiego; Xiao Jin; Tim Mulnix; Krista Fowles; David Labaree; Jim Ropchan; Yiyun Huang; Kelly Cosgrove; Stacy A Castner; Graham V Williams; Lisa Wells; Eugenii A Rabiner; Richard E Carson
Journal:  J Nucl Med       Date:  2013-10-10       Impact factor: 10.057

Review 5.  Neuroimaging markers of glutamatergic and GABAergic systems in drug addiction: Relationships to resting-state functional connectivity.

Authors:  Scott J Moeller; Edythe D London; Georg Northoff
Journal:  Neurosci Biobehav Rev       Date:  2015-12-01       Impact factor: 8.989

6.  Functional and structural correlates of the aging brain: relating visual cortex (V1) gamma band responses to age-related structural change.

Authors:  William Gaetz; Timothy P L Roberts; Krish D Singh; Suresh D Muthukumaraswamy
Journal:  Hum Brain Mapp       Date:  2011-07-18       Impact factor: 5.038

7.  Human biodistribution and dosimetry of the PET radioligand [¹¹C]flumazenil (FMZ).

Authors:  Charles M Laymon; Rajesh Narendran; Neale S Mason; Jonathan P Carney; Brian J Lopresti; Chester A Mathis; James M Mountz; Donald Sashin; W Gordan Frankle
Journal:  Mol Imaging Biol       Date:  2012-02       Impact factor: 3.488

8.  In vivo measurement of GABA transmission in healthy subjects and schizophrenia patients.

Authors:  W Gordon Frankle; Raymond Y Cho; Konasale M Prasad; N Scott Mason; Jennifer Paris; Michael L Himes; Christopher Walker; David A Lewis; Rajesh Narendran
Journal:  Am J Psychiatry       Date:  2015-07-02       Impact factor: 18.112

9.  Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

Authors:  Jee In Kang; Hae-Jeong Park; Se Joo Kim; Kyung Ran Kim; Su Young Lee; Eun Lee; Suk Kyoon An; Jun Soo Kwon; Jong Doo Lee
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

10.  Deficits in transcriptional regulators of cortical parvalbumin neurons in schizophrenia.

Authors:  David W Volk; Takurou Matsubara; Siyu Li; Elizabeth J Sengupta; Danko Georgiev; Yoshio Minabe; Allan Sampson; Takanori Hashimoto; David A Lewis
Journal:  Am J Psychiatry       Date:  2012-10       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.